Report on the Second PANLAR Review Course in Rheumatology: Biosimilars Update.

Thomas Dörner, Jonathan Kay, Biosimilars in rheumatology: current perspectives and lessons learnt Nature Reviews Rheumatology. ,vol. 11, pp. 713- 724 ,(2015) , 10.1038/NRRHEUM.2015.110

Judith C Macdonald, Helen Hartman, Ira A Jacobs, Regulatory considerations in oncologic biosimilar drug development mAbs. ,vol. 7, pp. 653- 661 ,(2015) , 10.1080/19420862.2015.1040973

Carlos Pineda, Carlo V. Caballero-Uribe, Marwin Gutiérrez, Tomás Cazenave, Mario H. Cardiel, Roger Levy, Graciela Espada, Carlos Rose, Pedro Santos-Moreno, Bernardo A. Pons-Estel, Roberto Muñoz-Louis, Enrique R. Soriano, John D. Reveille, Report on the First PANLAR Rheumatology Review Course Rheumatoid Arthritis: Challenges and Solutions in Latin America. Jcr-journal of Clinical Rheumatology. ,vol. 21, pp. 435- 439 ,(2015) , 10.1097/RHU.0000000000000318

Brian G. Feagan, Denis Choquette, Subrata Ghosh, Dafna D. Gladman, Vincent Ho, Bernd Meibohm, Guangyong Zou, Zhenhua Xu, Gopi Shankar, David C. Sealey, Anthony S. Russell, The challenge of indication extrapolation for infliximab biosimilars. Biologicals. ,vol. 42, pp. 177- 183 ,(2014) , 10.1016/J.BIOLOGICALS.2014.05.005

Carlos Pineda, Carlo V. Caballero-Uribe, Marcia Gonclaves de Oliveira, Pedro Saul Lipszyc, Jose Julian Lopez, Marcelo Mario Mataos Moreira, Valderilio Feijo Azevedo, Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view Clinical Rheumatology. ,vol. 34, pp. 635- 640 ,(2015) , 10.1007/S10067-015-2887-0

Valderílio Feijó Azevedo, Eduardo de Souza Meirelles, Jussara de Almeida Lima Kochen, Ana Cristina Medeiros, Sender J Miszputen, Fábio Vieira Teixeira, Adérson Osmar Mourão Cintra Damião, Paulo Gustavo Kotze, Ricardo Romiti, Marcelo Arnone, Renata Ferreira Magalhaes, Cláudia Pires Amaral Maia, André Vicente E de Carvalho, None, Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease--Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. Autoimmunity Reviews. ,vol. 14, pp. 769- 773 ,(2015) , 10.1016/J.AUTREV.2015.04.014

Howard Lee, Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars? The AAPS Journal. ,vol. 16, pp. 22- 26 ,(2014) , 10.1208/S12248-013-9534-Y

Hans C Ebbers, Stacy A Crow, Arnold G Vulto, Huub Schellekens, Interchangeability, immunogenicity and biosimilars Nature Biotechnology. ,vol. 30, pp. 1186- 1190 ,(2012) , 10.1038/NBT.2438

Rolando Espinosa Morales, Alejandro Díaz Borjón, Leonor Adriana Barile Fabris, Jorge Antonio Esquivel Valerio, Gabriel Medrano Ramírez, César Alejandro Arce Salinas, Eduardo Rubén Barreira Mercado, Mario Humberto Cardiel Ríos, Efraín Díaz Jouanen, Francisco Javier Flores Murrieta, Antonio Fraga Mouret, Mario Alberto Garza Elizondo, Miguel Luján Estrada, Francisco José Muñoz Barradas, Juan Osvaldo Talavera Piña, Olga Lidia Vera Lastra, Medicamentos biocomparables en México: la postura del Colegio Mexicano de Reumatología, 2012 Reumatología Clínica. ,vol. 9, pp. 113- 116 ,(2013) , 10.1016/J.REUMA.2012.11.001

Anoop Misra, Are biosimilars really generics Expert Opinion on Biological Therapy. ,vol. 10, pp. 489- 494 ,(2010) , 10.1517/14712591003662615